COVID-19, Sars-CoV-2 Infection
Conditions
Keywords
Voice
Brief summary
In some clinical forms of COVID-19, an uncontrolled hyper-inflammatory reaction known as a cytokine storm appears abruptly, around day 7, and is associated with rapid respiratory deterioration, requiring hospitalization in an intensive care unit (ICU). At present, although risk factors for this severe form have been described, there are no validated criteria for determining which individual patients will develop this aggravation. The study of respiratory sounds (amplitude, frequency, ...) has made it possible in other respiratory pathologies (e.g., chronic obstructive pulmonary disease) to predict exacerbations several days in advance. Having a predictive respiratory pattern for worsening in COVID-19 would make it possible to anticipate the need for intensive care hospital beds, by means of a tool easily available on a mobile phone.
Interventions
DEVICECOVOICE application use - initial
Recording (only once) of sound related to respiratory movements, coughing and voice using a mobile phone application
DEVICECOVOICE application use - follow-up
Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days
Sponsors
Direction Centrale du Service de Santé des Armées
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* French speaking * Affiliated to a social security system * Owning a mobile phone capable of accessing the COVOICE application
Exclusion criteria
* Incapable adults * People deprived of their liberty * People under administrative or judicial supervision * Patients intubated or hospitalized in intensive care unit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity of the respiratory pattern demonstrated in the COVID patients who experienced respiratory worsening | Through study completion (36 months) |
| Specificity of the respiratory pattern demonstrated in the COVID patients who experienced respiratory worsening | Through study completion (36 months) |
Countries
France
Contacts
Primary ContactHubety NIELLY, MD
Outcome results
None listed